Progression-free survival prolonged with sacituzumab govitecan plus pembrolizumab in triple-negative breast cancer

For patients with previously untreated, programmed death ligand 1 (PD-L1)-positive, locally advanced unresectable or metastatic triple-negative breast cancer (TNBC), sacituzumab govitecan plus pembrolizumab yields significantly longer progression-free survival than chemotherapy plus pembrolizumab, according to a study published in the Jan. 22 issue of the New England Journal of Medicine.

source https://medicalxpress.com/news/2026-01-free-survival-prolonged-sacituzumab-govitecan.html